TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer
Daniela Bossi, Arianna Vallerga, Giuseppe Salfi, Nicolò Formaggio, Valentina Ceserani, Zhang Jichang, Tiziano Bernasocchi, Andrea Rinaldi, Lukas Bubendorf, Simone Mosole, Eva Corey, Marco Bolis, Matteo Pecoraro, Roger Geiger, Wouter R. Karthaus, , Jean-Philippe Paul. Theurillat
This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.
bioRxiv · Aug 21, 2025 · PreprintCancer Biology